🔓 Free Teaser Analysis Nephrology / Renal Pharmacy Confirmatory Grade: Moderate
Finerenone emerges as the safer choice for CKD patients.
🔓 Free Teaser Analysis Neurology / Neuropharmacology Confirmatory Grade: Low
Tenecteplase speeds up stroke thrombolysis compared to alteplase.
🔓 Free Teaser Guideline Rheumatology / Immunology Confirmatory Grade: Moderate
New EULAR guidelines redefine RA management with DMARDs.
🔓 Free Teaser Guideline Dyslipidemia Practice-changing Grade: Moderate
The 2026 ACC/AHA/Multisociety guideline introduces lower treatment goals, formal risk equations, and mandates Lp(a) assessment for dyslipidemia pharmacists.
🔓 Free Teaser Guideline Diabetes Practice-changing Grade: Moderate
Introduces expanded diabetes screening and diagnostic recommendations across diverse populations for pharmacy practice.
🔓 Free Teaser Guideline Hypertension Practice-changing Grade: Moderate
The 2025 AHA/ACC Guideline introduces PREVENT-based CVD risk, new secondary hypertension triggers, and major changes in initial drug therapy for pharmacists managing hypertension.
🔓 Free Teaser Analysis Critical Care / ICU
The A2B trial evaluates sedation strategies on extubation timing in critical care.
🔓 Free Teaser Guideline Immunization Practice-changing Grade: Moderate
The 2025 ACIP adult schedule features universal and risk-based expansions for pneumococcal, RSV, and polio vaccines, plus product, schedule, and note updates directly relevant to pharmacists.
🔓 Free Teaser Analysis Cardiology Confirmatory Grade: Moderate
The largest, most rigorous trial of in-hospital sodium-glucose cotransporter-2 inhibitor initiation was formally neutral, but pooled trial data continue to support early inpatient start for hospitalized heart failure patients.
🔓 Free Teaser Guideline AFib/Antithrombotics Practice-changing Grade: Moderate
Major changes in stroke risk assessment, anticoagulant preferences, and DOAC over warfarin guidance will alter daily pharmacist management of AFib patients.
🔓 Free Teaser Guideline Beers Criteria Practice-changing Grade: Moderate
The 2023 AGS Beers Criteria update introduces significant modifications and new recommendations impacting antihyperglycemics, anticoagulants, anticholinergics, and select drug–disease interactions for older adults.
🔓 Free Teaser Guideline COPD Practice-changing Grade: Moderate
The GOLD 2026 update brings significant changes impacting risk stratification, exacerbation management, biologics, and vaccination in COPD care.
🔓 Free Teaser Guideline Heart Failure Practice-changing Grade: Moderate
The 2022 AHA/ACC/HFSA guideline redefines heart failure subtypes and updates foundational recommendations for GDMT, SGLT2 inhibitors, and phenotype-directed care.
🔓 Free Teaser Guideline Clostridioides difficile Infection Practice-changing Grade: High
This guideline prioritizes fidaxomicin over vancomycin and updates on adjunct therapies.
🔓 Free Teaser Guideline Community-Acquired Pneumonia Practice-changing Grade: Moderate
The 2019 ATS/IDSA CAP guideline introduces major shifts in diagnostic and empiric therapy strategies for adult patients.